July 14, 2020, Salt Lake City, UT— PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today announced a collaboration with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center to conduct an at home, telemedicine, phase 3 trial to establish safety and efficacy for the company’s non-invasive specialized phototherapy device for Parkinson’s disease.
FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease...
View the full release on EIN Newswire Largest Phototherapy Trial for Parkinson’s Disease...
Pivotal Parkinson’s Disease Clinical Trial Results Released at the International Movement Disorders Society Congress
View the full release on BusinessWirePivotal Parkinson’s Disease Clinical Trial Results Released...
We at PhotoPharmics are passionate about representing the Parkinson’s community in an effort to raise awareness. In a recent survey, PhotoPharmics discovered a large percentage of people are waiting with great eagerness for breakthroughs that will improve the standard of care for people with Parkinson’s. Read more >
Living with a Parkinson’s diagnosis? People with PD offer advice, words of encouragementPeople with Parkinson’s discuss ways they cope with their disease
More than a million people every year are living with Parkinson’s disease in the United States. Over 60,000 are diagnosed every year, and many more are suffering without a formal diagnosis. It’s likely your life or the life of someone you love has been affected by Parkinson’s disease in one way or another. Read more >
The Holiday season can be the most joyful, wonderful time of the year. It can also be complicated, stressful and depressing. This is true for everyone, but people with Parkinson’s disease have an especially unique perspective on this festive time of year. Read more >